Randomized trial also suggests lower recurrence rate.

Phase 2 data support use of VEGF inhibitors to enhance IL-2 benefit.

Dysplastic nevi may be phenotypic markers rather than obligate precursors.

Phase 1b data show 90% rate of serious adverse events.

Combination therapy yields better response rates but substantially higher toxicity.

Real-world data supports ixekizumab as a treatment choice.

Biologic agents show benefit.

Population study identifies prognostic factors in mucosal and cutaneous melanoma.

Predictive tool may help prevent unnecessary hospital admissions.

The World Medical Association has published a series of new recommendations to achieve gender equality in medicine.

Only 7 per cent of cancer patients using alternative therapies discussed safety issues with their oncologist.

Atorvastatin reduced swelling, itching, pain.

The 1 exception is thyroiditis.

Peter Gøtzsche, an outspoken critic of recent Cochrane reviews, was sacked from the Board of the Cochrane Collaboration in September.